AR079510A1 - Derivados de quinolinamida moduladores alostericos positivos de receptores muscarinicos m1, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del alzheimer, esquizofrenia y otras patologias del sistema nervioso central. - Google Patents
Derivados de quinolinamida moduladores alostericos positivos de receptores muscarinicos m1, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del alzheimer, esquizofrenia y otras patologias del sistema nervioso central.Info
- Publication number
- AR079510A1 AR079510A1 ARP100104723A ARP100104723A AR079510A1 AR 079510 A1 AR079510 A1 AR 079510A1 AR P100104723 A ARP100104723 A AR P100104723A AR P100104723 A ARP100104723 A AR P100104723A AR 079510 A1 AR079510 A1 AR 079510A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- group
- ring
- halogen
- atoms
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
- C07D215/60—N-oxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Quinoline Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Reivindicacion 1: Un compuesto de la formula (1) donde X1 se selecciona del grupo que consiste en (1) N, y (2) N«O; X2-X3 se selecciona del grupo que consiste en (1) -CH2-CH2-, (2) -O-CH2-, (3) -CH2-O-, o (4) -CH2-; cada uno de X4, X5, X6 y X7 se selecciona del grupo que consiste en (1) N, (2) N«O, (3) CH, (4) O, siempre que uno de X4, X5, X6 y X7 puede estar ausente, con lo cual forma un anillo de cinco miembros; R1 selecciona del grupo que consiste en (1) hidrogeno, (2) halogeno, (3) -alquilo C1-6, (4) -alquinilo C2-6, (4) fenilo, (5) =O, (6) =CH2, (7) hidroxilo, donde el grupo alquilo, alquinilo o fenilo R1 está opcionalmente sustituido con uno o más (a) hidroxilo, o (b) halogeno; R2A y R2B, seleccionan -de manera independiente- del grupo que consiste en (1) hidrogeno, (2) hidroxilo, y (3) halogeno, o R2A y R2B juntos forman =O; R3 está opcionalmente presente en uno o más de los átomos de carbono del anillo, y se selecciona -de manera independiente- del grupo que consiste en (1) halogeno, (2) -O-alquilo C1-6, (3) -S-alquilo C1-6, o (4) un grupo heteroarilo, que es un grupo cíclico aromático, que tiene entre cinco y doce átomos en el anillo; dichos átomos del anillo se seleccionan de C, O, N, N«O o S, al menos uno de los cuales es O, N, N«O o S, donde el heteroarilo está opcionalmente sustituido con alquilo C1-6; R4 está opcionalmente presente en uno o más de los átomos del anillo y se selecciona del grupo que consiste en (1) hidroxilo, (2) halogeno, (3) -alquilo C1-6, (4) -O-alquilo C1-6, (5) -S-alquilo C1-6, (6) -cicloalquilo C3-8, (7) -arilo C6-10, (8) -CN, (9) un grupo heteroarilo, que es un grupo cíclico aromático, que tiene entre cinco y doce átomos en el anillo; dichos átomos del anillo se seleccionan de C, O, N, N«O o S, al menos uno de los cuales es O, N, N«O o S, (10) -O-heterociclilo, (11) -NRARB, donde RA y RB se seleccionan del grupo que consiste en (a) hidrogeno, o (b) -alquilo C1-6, o RA y RB están unidos junto con el nitrogeno al cual están adheridos para formar un anillo carbocíclico de 4-6 miembros, donde uno o dos de los átomos de carbono del anillo está opcionalmente reemplazado por un nitrogeno, oxígeno o azufre, y el anillo está opcionalmente sustituido con uno o más (a) halogeno, (b) hidroxilo, (c) alquilo C1-6, (d) -O-alquilo C1-6, (e) -C(=O)-(O)n-alquilo C1-6; donde n es 0-1; y el grupo alquilo, cicloalquilo, arilo o heteroarilo R4 está opcionalmente sustituido con uno o más (a) halogeno, (b) hidroxi, (c) -O-alquilo C1-6, (d) -alquilo C1-6, (e) -S-alquilo C1-6, o (f) un grupo heteroarilo, que es un grupo cíclico aromático, que tiene entre cinco y doce átomos en el anillo; dichos átomos del anillo se seleccionan de C, O, N, N«O o S, al menos uno de los cuales es O, N, N«O o S, donde la fraccion alquilo, arilo o heteroarilo está opcionalmente sustituida con uno o más (i) halogeno, (ii) hidroxi, (iii) -O-alquilo C1-6, o (iv) -alquilo C1-6; o dos grupos R4 están unidos juntos para formar un grupo heteroarilo en anillo fusionado de tres o cuatro átomos; dichos átomos del anillo se seleccionan de C, O, N, N«O o S, al menos uno de los cuales es O, N, N«O o S, o una de sus sales farmacéuticamente aceptables.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28753509P | 2009-12-17 | 2009-12-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR079510A1 true AR079510A1 (es) | 2012-02-01 |
Family
ID=44305688
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP100104723A AR079510A1 (es) | 2009-12-17 | 2010-12-17 | Derivados de quinolinamida moduladores alostericos positivos de receptores muscarinicos m1, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del alzheimer, esquizofrenia y otras patologias del sistema nervioso central. |
Country Status (41)
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10164139A1 (de) | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-Heteroarylcarbonsäureamide |
US9101612B2 (en) * | 2010-02-11 | 2015-08-11 | Northwestern University | Secondary structure stabilized NMDA receptor modulators and uses thereof |
CA2989633A1 (en) | 2010-05-17 | 2011-11-24 | Forum Pharmaceuticals Inc. | A crystalline form of (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate |
EP2582676B1 (en) | 2010-06-15 | 2016-12-14 | Merck Sharp & Dohme Corp. | Tetrahydroquinoline amide m1 receptor positive allosteric modulators |
US8940765B2 (en) * | 2011-05-17 | 2015-01-27 | Merck Sharp & Dohme Corp. | N-linked quinolineamide M1 receptor positive allosteric modulators |
US9403802B2 (en) | 2012-03-02 | 2016-08-02 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use therefor |
CA2872005A1 (en) | 2012-05-08 | 2013-11-14 | Forum Pharmaceuticals, Inc. | Methods of maintaining, treating or improving cognitive function |
JP6211530B2 (ja) | 2012-11-19 | 2017-10-11 | 武田薬品工業株式会社 | 含窒素複素環化合物 |
TW201512197A (zh) * | 2013-08-30 | 2015-04-01 | Hoffmann La Roche | 吡咯并吡啶或吡唑并吡啶衍生物 |
JP6185660B2 (ja) * | 2013-09-27 | 2017-08-23 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | インドール及びインダゾール誘導体 |
GB201317363D0 (en) * | 2013-10-01 | 2013-11-13 | Eisai Ltd | Novel compounds |
CA2930961A1 (en) * | 2014-01-22 | 2015-07-30 | F. Hoffmann-La Roche Ag | Fluoro-naphthyl derivatives |
WO2015190564A1 (ja) * | 2014-06-13 | 2015-12-17 | 武田薬品工業株式会社 | 含窒素複素環化合物 |
WO2016009297A1 (en) | 2014-07-18 | 2016-01-21 | Pfizer Inc. | Pyridine derivatives as muscarinic m1 receptor positive allosteric modulators |
CA2988468A1 (en) | 2015-06-09 | 2016-12-15 | Bayer Pharma Aktiengesellschaft | A 7-substituted-1-aryl-naphthyridin-3-carboxylic acid amide and its use as a positive allosteric modulator of the muscarinic m2 receptor |
LT3347349T (lt) * | 2015-09-10 | 2019-12-10 | Suven Life Sciences Ltd | Fluorindolo dariniai kaip muskarininio m1 receptoriaus teigiami alosteriniai moduliatoriai |
WO2017099969A1 (en) * | 2015-12-10 | 2017-06-15 | Merck Sharp & Dohme Corp. | Tetrahydroquinoxaline m1 receptor positive allosteric modulators |
EA201891854A1 (ru) | 2016-02-16 | 2019-01-31 | Вандербилт Юниверсити | Положительные аллостерические модуляторы мускаринового ацетилхолинового рецептора m |
WO2017151449A1 (en) * | 2016-03-04 | 2017-09-08 | Merck Sharp & Dohme Corp. | M1 receptor positive allosteric modulator compounds and methods of use thereof |
EP3481823B1 (de) | 2016-07-11 | 2020-10-28 | Bayer Pharma Aktiengesellschaft | 7-substituierte 1-pyridyl-naphthyridin-3-carbonsäureamide und ihre verwendung |
EP3507289B1 (en) | 2016-09-02 | 2020-07-15 | Suven Life Sciences Limited | Muscarinic m1 receptor positive allosteric modulators |
JOP20190045A1 (ar) | 2016-09-14 | 2019-03-14 | Bayer Ag | مركبات أميد حمض 1- أريل-نفثيريدين-3-كربوكسيليك مستبدلة في الموضع 7 واستخدامها. |
WO2018063552A1 (en) | 2016-09-30 | 2018-04-05 | Vanderbilt University | Positive allosteric modulators of the muscarinic acetylcholine receptor m1 |
EA035599B1 (ru) * | 2017-04-13 | 2020-07-14 | Сувен Лайф Сайенсиз Лимитед | Позитивные аллостерические модуляторы мускариновых m1-рецепторов |
AU2018289939B2 (en) * | 2017-06-20 | 2022-06-16 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
ES2960408T3 (es) | 2017-06-20 | 2024-03-04 | Takeda Pharmaceuticals Co | Compuesto heterocíclico y su uso como modulador alostérico positivo del receptor M1 muscarínico colinérgico |
CN111278814B (zh) * | 2017-10-27 | 2022-10-28 | 苏文生命科学有限公司 | 作为毒蕈碱m1受体正向别构调节剂的多环酰胺 |
JP7446232B2 (ja) | 2018-09-28 | 2024-03-08 | 武田薬品工業株式会社 | 縮合環化合物 |
EP3858828A4 (en) * | 2018-09-28 | 2022-07-06 | Takeda Pharmaceutical Company Limited | HETEROCYCLIC COMPOUND |
WO2020079606A1 (en) | 2018-10-17 | 2020-04-23 | Suven Life Sciences Limited | Pyrrolo-pyridazine derivatives as muscarinic m1 receptor positive allosteric modulators |
WO2020086864A1 (en) | 2018-10-24 | 2020-04-30 | Vanderbilt University | Positive allosteric modulators of the muscarinic acetylcholine receptor m1 |
WO2023114224A1 (en) | 2021-12-13 | 2023-06-22 | Sage Therapeutics, Inc. | Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL135495A (en) | 1995-09-28 | 2002-12-01 | Hoechst Ag | Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid |
EP1314726A4 (en) | 2000-08-29 | 2005-07-13 | Yamanouchi Pharma Co Ltd | NEW ESTER OR AMID DERIVATIVES |
WO2004073639A2 (en) | 2003-02-19 | 2004-09-02 | Merck & Co. Inc. | Treatment of psychosis with a muscarinic m1 receptor ectopic activator |
JP2006519846A (ja) * | 2003-03-10 | 2006-08-31 | シェーリング コーポレイション | 複素環式キナーゼインヒビター:使用および合成の方法 |
SE0302139D0 (sv) * | 2003-07-28 | 2003-07-28 | Astrazeneca Ab | Novel compounds |
US7834010B2 (en) | 2003-12-23 | 2010-11-16 | Serodus As | Modulators of peripheral 5-HT receptors |
WO2005094834A1 (en) * | 2004-03-17 | 2005-10-13 | Glaxo Group Limited | Muscarinic acetylcholine receptor antagonists |
CN101321733A (zh) * | 2005-12-05 | 2008-12-10 | 默克公司 | 喹诺酮m1受体阳性变构调节剂 |
US8389545B2 (en) * | 2005-12-05 | 2013-03-05 | Merck, Sharp & Dohme, Corp. | Quinolone M1 receptor positive allosteric modulators |
PE20091036A1 (es) | 2007-11-30 | 2009-08-15 | Astrazeneca Ab | Derivado de quinolina como antagonista del receptor p2x7 |
US8173672B2 (en) * | 2008-03-21 | 2012-05-08 | Merck Sharp & Dohme Corp. | Quinolizidinone M1 receptor positive allosteric modulators |
MY162502A (en) | 2008-11-20 | 2017-06-15 | Merck Sharp & Dohme | Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators |
WO2010096338A1 (en) | 2009-02-23 | 2010-08-26 | Merck Sharp & Dohme Corp. | PYRAZOLO [4,3-c] CINNOLIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS |
EP2421366B1 (en) | 2009-04-20 | 2013-08-28 | Merck Sharp & Dohme Corp. | Heterocyclic fused cinnoline m1 receptor positive allosteric modulators |
MX2012002583A (es) | 2009-08-31 | 2012-04-02 | Merck Sharp & Dohme | Moduladores de piranil aril metil benzoquinazolinona alostericos positivos del receptor m1. |
WO2011049731A1 (en) | 2009-10-21 | 2011-04-28 | Merck Sharp & Dohme Corp. | Quinolinone-pyrazolone m1 receptor positive allosteric modulators |
EP2501231B1 (en) | 2009-11-20 | 2016-12-21 | Merck Sharp & Dohme Corp. | Quinolizidinone carboxamide m1 receptor positive allosteric modulators |
WO2011075371A1 (en) | 2009-12-14 | 2011-06-23 | Merck Sharp & Dohme Corp. | Pyridoquinazolinone m1 receptor positive allosteric modulators |
US8383638B2 (en) | 2009-12-21 | 2013-02-26 | Merck Sharp & Dohme | Aminobenzoquinazolinone M1 receptor positive allosteric modulators |
US8883850B2 (en) | 2010-05-28 | 2014-11-11 | Merck Sharp & Dohme Corp. | Naphthalene carboxamide M1 receptor positive allosteric modulators |
EP2582676B1 (en) | 2010-06-15 | 2016-12-14 | Merck Sharp & Dohme Corp. | Tetrahydroquinoline amide m1 receptor positive allosteric modulators |
WO2011159553A1 (en) | 2010-06-15 | 2011-12-22 | Merck Sharp & Dohme Corp. | Heterocyclic fused phenanthrolinone m1 receptor positive allosteric modulators |
US8940765B2 (en) | 2011-05-17 | 2015-01-27 | Merck Sharp & Dohme Corp. | N-linked quinolineamide M1 receptor positive allosteric modulators |
-
2010
- 2010-12-13 PT PT108418211T patent/PT2512243E/pt unknown
- 2010-12-13 ES ES10841821.1T patent/ES2575154T3/es active Active
- 2010-12-13 WO PCT/US2010/060007 patent/WO2011084368A1/en active Application Filing
- 2010-12-13 BR BR112012014180A patent/BR112012014180A2/pt active Search and Examination
- 2010-12-13 UA UAA201208772A patent/UA106406C2/ru unknown
- 2010-12-13 PL PL10841821.1T patent/PL2512243T3/pl unknown
- 2010-12-13 EP EP10841821.1A patent/EP2512243B1/en active Active
- 2010-12-13 DK DK10841821.1T patent/DK2512243T3/en active
- 2010-12-13 JP JP2012544670A patent/JP5651708B2/ja not_active Expired - Fee Related
- 2010-12-13 HU HUE10841821A patent/HUE029734T2/en unknown
- 2010-12-13 CN CN201080057292.2A patent/CN102651970B/zh not_active Expired - Fee Related
- 2010-12-13 ME MEP-2016-106A patent/ME02421B/me unknown
- 2010-12-13 GE GEAP201012786A patent/GEP201606506B/en unknown
- 2010-12-13 US US13/515,724 patent/US9199939B2/en active Active
- 2010-12-13 MX MX2012007013A patent/MX336774B/es unknown
- 2010-12-13 CA CA2782347A patent/CA2782347C/en not_active Expired - Fee Related
- 2010-12-13 RS RS20160369A patent/RS54798B1/sr unknown
- 2010-12-13 AU AU2010340142A patent/AU2010340142B2/en not_active Ceased
- 2010-12-13 SI SI201031184A patent/SI2512243T1/sl unknown
- 2010-12-13 MA MA35061A patent/MA33920B1/fr unknown
- 2010-12-13 EA EA201290519A patent/EA022494B1/ru not_active IP Right Cessation
- 2010-12-13 SG SG2012044095A patent/SG181719A1/en unknown
- 2010-12-13 NZ NZ600674A patent/NZ600674A/xx not_active IP Right Cessation
- 2010-12-13 KR KR1020127015521A patent/KR101494059B1/ko active IP Right Grant
- 2010-12-13 PE PE2012000830A patent/PE20121613A1/es not_active Application Discontinuation
- 2010-12-16 TW TW099144262A patent/TWI412525B/zh not_active IP Right Cessation
- 2010-12-17 AR ARP100104723A patent/AR079510A1/es unknown
-
2012
- 2012-05-17 TN TNP2012000231A patent/TN2012000231A1/en unknown
- 2012-06-03 IL IL220130A patent/IL220130A0/en unknown
- 2012-06-12 ZA ZA2012/04313A patent/ZA201204313B/en unknown
- 2012-06-14 HN HN2012001265A patent/HN2012001265A/es unknown
- 2012-06-14 CL CL2012001605A patent/CL2012001605A1/es unknown
- 2012-06-15 GT GT201200201A patent/GT201200201A/es unknown
- 2012-06-15 CR CR20120327A patent/CR20120327A/es unknown
- 2012-06-15 NI NI201200107A patent/NI201200107A/es unknown
- 2012-06-15 CO CO12101581A patent/CO6551729A2/es unknown
- 2012-06-15 DO DO2012000167A patent/DOP2012000167A/es unknown
- 2012-06-19 EC ECSP12011983 patent/ECSP12011983A/es unknown
- 2012-10-30 HK HK12110914.8A patent/HK1170122A1/zh not_active IP Right Cessation
-
2015
- 2015-11-18 US US14/945,005 patent/US20160075656A1/en not_active Abandoned
-
2016
- 2016-05-27 HR HRP20160574TT patent/HRP20160574T1/hr unknown
- 2016-07-05 CY CY20161100625T patent/CY1117726T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR079510A1 (es) | Derivados de quinolinamida moduladores alostericos positivos de receptores muscarinicos m1, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del alzheimer, esquizofrenia y otras patologias del sistema nervioso central. | |
CO2019003349A2 (es) | Compuestos de benzo[b]tiofeno como agonistas de sting | |
ES2521596T3 (es) | Combinación del compuesto GlyT1 con antipsicóticos | |
AR052568A1 (es) | Derivados de pirazolo -pirimidina como antagonstas de mglur2 | |
CO6251264A2 (es) | Derivados de 1-ciano ciclopropilo como inhibidores de la captesina k | |
PE20130306A1 (es) | Morfolinopirimidinas y su uso en terapia | |
AR074358A1 (es) | Derivados de pirazina como inhibidores de la fosfodiesterasa 10 | |
AR067757A1 (es) | Derivados de imidazo[4,5-c]piridin-2-ona, composiciones farmaceuticas que los contienen, procedimiento para su preparacion y uso de los mismos como agentes antivirales. | |
AR078152A1 (es) | Compuestos heterociclicos, utiles para el tratamiento de hcv y composiciones farmaceuticas que los comprenden | |
AR089774A1 (es) | Derivados de indolizina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
AR080074A1 (es) | Naftiridinas sustituidas y su uso como medicamentos | |
ECSP12012161A (es) | Compuestos en calidad de antagonistas de Bradiquinina-b1 | |
UY34723A (es) | ?compuestos de 7-oxo-1,6-diazabiciclo[3.2.1]oct-3-en-6-ilo sustituidos para usarse como inhibidores de la betalactamasa?. | |
AR077695A1 (es) | Derivados de pirimidina como inhibidores del factor ixa | |
NI200700270A (es) | Derivados benzodioxano y benzodioxolano y usos de los mismos | |
UY33458A (es) | Derivados de metoxifenilo heterocíclicamente sustituidos con un grupo oxo, procedimientos para su preparación y uso de los mismos como medicamentos | |
UY28848A1 (es) | Antagonistas de cgrp seleccionados, procedimientos para su preparación, y su empleo como medicamentos | |
AR063988A1 (es) | Derivados heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
AR067662A1 (es) | Derivados de benzo[d]isoxazol-3-il-piperidina, medicamentos que los contienen y usos terapeuticos para enfermedades asociadas al sistema nervioso. | |
AR079553A1 (es) | Derivados de diaza-espiro-[5,5]-undecanos, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos del snc, tales como trastornos del sueno y de la dependencia,entre otros. | |
UY29749A1 (es) | Antagonistas de cgrp seleccionados, procedimientos para su preparación, así como su uso como medicamentos | |
AR070187A1 (es) | Derivados de dulfonamidas sustituidas | |
AR070648A1 (es) | Derivados de bencimidazol sustituido | |
CU23761B7 (es) | Nuevos derivados de diosmetina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
AR102989A1 (es) | Compuestos antibacterianos con acción sobre topoisomerasas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |